We are only at the very beginning of this. It is starting to be implemented for cancer in particular. We are starting to see a number of types of cancer for which there are biomarkers and we know which tumour is going to respond to which drug. As a result, we can give such and such a drug to a patient who has a given biomarker. We believe that we can extend this approach to a large number of drugs, but the research is still in its infancy.
You referred to Alzheimer's. There is no personalized medicine for Alzheimer's yet because we do not yet understand the basic mechanisms responsible for the neurodegeneration that we see in Alzheimer's. Once we understand those mechanisms and we identify the genetic profile responsible for the onset of the disease or a predisposition, we will be able to have more appropriate treatments.